EP0253302B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Tetrahydronaphthalène and indane derivatives, their synthesis and application in pharmaceutical preparations
Assignee: F Hoffmann La Roche AG
•
Filing: 1987-07-08
•
Granted: 1994-09-14
•
Expires: 2007-07-08
Abstract
No abstract record available.
Inventors
- 👤 Michael Dr. Klaus
- 👤 Ekkehard Dr. Weiss
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-30 17:43
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/04; C07D213/00; C07D213/02; C07D213/04; C07D213/06; C07D213/16; A; A61; A61P; A61P17/00; A61P29/00; A61P35/00; A61P37/00; A61P37/08; C07D239/00; C07D239/02; C07D239/24; C07D239/26; C07D307/00; C07D307/02; C07D307/34; C07D307/36; C07D333/00; C07D333/02; C07D333/04; C07D333/06; C07D333/08
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
94 words
Compounds of the general formula wherein X and Y represent -CH₂- or >C(CH₃)₂; Z represents a residue -CHR⁸-, >CO, >CR⁸OR⁷, -CHR⁸-CHR⁸-, -CHOR⁷-CH₂-, -CO-CHOR⁷ or -CHOR⁷-CHOR⁷-; R¹ represents pyridyl, R² and R³ represent hydrogen, C₁₋₆-alkyl, trifluoromethyl or halogen and one of the residues R² and R³ represents trifluoromethyl or C₁₋₆-alkyl, R⁴ and R⁵ represent hydrogen, C₁₋₁₀-alkyl, C₁₋₁₀-alkoxy or halogen; R⁶ represents hydrogen, C₁₋₆-alkyl or a residue -OR⁷; R⁷ represents hydrogen, C₁₋₆-alkyl, C₁₋₆-alkanoyl, benzoyl, p-nitrobenzoyl, toluoyl or phenylacetyl; R⁸ represents hydrogen or C₁₋₆-alkyl; and several residues R⁷ or R⁸ present can be different from one another.
Claim 2
Dependent Claim
33 words
Compounds in accordance with claim 1 in which X and Y represent >C(CH₃)₂; Z represent -CH₂-CH₂-, R¹ represents pyridyl; R², R⁵ and R⁶ represent hydrogen; and R⁴ represents hydrogen or C₁₋₁₀-alkyl or C₁₋₁₀-alkoxy.
Claim 3
Dependent Claim
1 words
4-[(E)2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.
Claim 4
Dependent Claim
1 words
3-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.
Claim 5
Dependent Claim
1 words
2-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-propenyl]pyridine.
Claim 6
Dependent Claim
11 words
The compounds in accordance with claims 1-5 for use as medicaments.
Claim 7
Dependent Claim
23 words
The use of the compounds in accordance with claims 1-5 for the manufacture of pharmaceutical preparations for the treatment of neoplasms and dermatoses.
Claim 8
Dependent Claim
15 words
Pharmaceutical preparations containing a compound in accordance with claims 1-5 and a pharmaceutical carrier material.
Claim 9
Dependent Claim
19 words
Pharmaceutical preparations in accordance with claim 8 containing 5-200 mg of a compound of claims 1-5 per dosage unit.
Claim 10
Dependent Claim
123 words
A process for the manufacture of the compounds of claims 1-5, characterized by reacting a compound of the general formula with a compound of the general formula R¹-B in which either A represents the residue -CH(R³)P⁺(Q)₃Y⁻ or -CH(R3)-P(O)(OAlk)₂ and B represents a residue R²¹-CO-; or A represents a residue R³¹-CO- and B represents one of the residues -CH(R²)P⁺(Q)₃Y⁻, or -CH(R²)-P(O)(OAlk)₂ or -CH(R²¹)MgHal; or A represents a residue -CH(R³¹)MgHal and B represents a residue R²-CO-; whereby in the above formulae Q is aryl; Y- is the anion of an organic or inorganic acid; Alk is a C₁₋₆-alkyl group; Hal is halogen; R²¹ and R³¹ are hydrogen, trifluoromethyl or C₁₋₆-alkyl; and R¹, R², R³, R⁴, R⁵, X, Y and Z have the significance given above.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.